What is Antabio?
Antabio operates at the intersection of biotechnology and public health, specializing in the development of novel antibacterial treatments. The company is primarily focused on combating life-threatening respiratory infections, specifically those caused by carbapenem-resistant nosocomial pneumonia and chronic pulmonary diseases. Its lead program, MEM-ANT3310, represents a significant advancement in the treatment of hospital-acquired infections, including those caused by CRAB and CRE pathogens. By targeting these critical priority pathogens, Antabio positions itself as a key player in the global effort to mitigate the risks associated with antimicrobial resistance (AMR).
How much funding has Antabio raised?
Antabio has raised a total of $38.3M across 3 funding rounds:
Share Placement
$2.8M
Series A
$8.6M
Series B
$26.9M
Share Placement (2017): $2.8M with participation from Carb-X
Series A (2017): $8.6M led by IRDI SORIDEC Gestion, Galia Gestion, and iXO Private Equity
Series B (2023): $26.9M supported by The AMR Action Fund and BNP Paribas Développement
Key Investors in Antabio
The AMR Action Fund
The AMR Action Fund is dedicated to overcoming technical and funding barriers in antibiotic development, aiming to ensure a sustainable pipeline of new antibiotics to combat superbugs.
BNP Paribas Développement
BNP Paribas Développement is a subsidiary of the international banking group BNP Paribas, dedicated to investing its own funds to support the long-term development of SMEs and mid-sized companies.
IRDI SORIDEC Gestion
Irdi Soridec Gestion is a company that operates in the Venture Capital & Private Equity industry, focusing on supporting regional growth and innovation.
What's next for Antabio?
With the recent capital injection, Antabio is well-positioned to accelerate the clinical development of its lead programs. The strategic focus will likely shift toward expanding trial capabilities and navigating the regulatory pathways required to bring these essential therapies to market. As the company scales, it will continue to leverage its partnerships with organizations like the AMR Action Fund to ensure that its innovative pipeline remains aligned with the urgent, unmet needs of the global healthcare system. Future milestones will likely center on clinical data readouts and the potential for commercialization of its differentiated antibacterial portfolio.
See full Antabio company page
